文献速递浆细胞疾病

三联和四联诱导治疗时代原发难治性多发性骨髓瘤患者的结局

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
PubMed 文献 · Blood Adv · 2023-01-01

本研究回顾性分析了本机构接受三联或四联治疗的1127例多发性骨髓瘤患者,其中1086例在4至6个周期后评估血液学反应,6.7%(73例)为原发难治性疾病。原发难治患者总生存期缩短风险增加(单变量HR 3.5,多变量HR 4.3),接受二线自体干细胞移植者二次无进展生存和二次总生存均优于未接受者。

要点

  • 原发难治性疾病发生率为6.7%(73/1086),与较短总生存期相关(多变量HR 4.3)。
  • 原发难治患者中,二线自体干细胞移植者二次无进展生存20.9个月 vs 8.1个月(P < .01)。
  • 二线自体干细胞移植者二次总生存74.7个月 vs 31.3个月(P = .02)。

核心结论

  • 在当前时代,早期进展仍是总生存期缩短的重要因素,挽救性自体干细胞移植可能是该人群最有益的选项。

研究设计与样本

  • 回顾性分析本机构接受三联或四联治疗的多发性骨髓瘤患者,共识别1127例,其中1086例在4至6个周期后评估血液学反应。

主要发现

  • 93.3%(1013例)有反应证据,6.7%(73例)为原发难治性疾病。
  • 原发难治患者总生存期中位数为51.3个月,单变量分析风险比HR 3.5(95%CI 2.5-4.9),多变量分析HR 4.3(95%CI 2.6-6.9)。
  • 原发难治亚组中,接受二线自体干细胞移植者二次无进展生存20.9个月 vs 未接受者8.1个月(P < .01)。
  • 原发难治亚组中,接受二线自体干细胞移植者二次总生存74.7个月 vs 未接受者31.3个月(P = .02)。

临床怎么用

  • 作者认为,挽救性自体干细胞移植可能是原发难治性多发性骨髓瘤人群最有益的选项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with multiple myeloma (MM) who do not respond to initial therapy have worse outcomes than primary responders, and effective treatments are lacking in this population. However, the outcomes of primary refractory disease in the modern treatment era have not yet been studied. We reviewed patients with MM treated with triplet/quadruplet therapy at our institution to assess the incidence of primary refractory disease and the impact of salvage therapies in this population. We identified 1127 patients, of whom 1086 were evaluated for hematologic responses after 4 to 6 cycles. Of these, 93.3% (1013) had evidence of response, whereas 6.7% (73) had primary refractory disease. With a median overall survival (OS) of 51.3 months, patients with primary refractory disease had an increased risk of shorter survival in univariable and multivariable analyses (hazard ratio [HR], 3.5 [95% confidence interval (CI), 2.5-4.9]; HR, 4.3 [95% CI, 2.6-6.9], respectively). In the subgroup analysis of patients with primary refractory disease, those who received second-line autologous stem cell transplantation (ASCT) had increased second progression-free survival (20.9 vs 8.1 months; P < .01) and second OS (74.7 vs 31.3 months; P = .02) compared with patients who did not. We conclude that early progression remains a significant factor for shorter OS in the current era, and salvage ASCT could be the most beneficial option for this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Charalampous C, Goel U, Kapoor P, et al. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023. PMID: 37603349. doi:10.1182/bloodadvances.2023009681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。